RadioMedix, Inc.
PrivateLast Round
Series A
Oct 7, 2022
Total Funding Raised
$44M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
RadioMedix, Inc. is a biotechnology company that develops and commercializes targeted radiopharmaceuticals for the diagnosis, monitoring, and therapy of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Pharma Supply Chain, Medical Imaging
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
RadioMedix, Inc. Comparables
Compare RadioMedix, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ratio Therapeutics Inc. | 77% | |
| AdvanCell | 76% | |
| Aktis Oncology | 76% | |
RadioMedix, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 7, 2022 | ||||
| Grant | Nov 18, 2021 | ||||
| Grant | Jan 22, 2019 |
RadioMedix, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| NIH RADx | Grant |
| Portland Investment Counsel Inc. | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors grew 102% MoM, reaching 2.6K.
- Jul 17, 2026
Open roles increased to 14, 3.5x the trailing average.
RadioMedix, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |